ArticleNature biotechnology2012
Navigating cancer network attractors for tumor-specific therapy.
Article in Nature biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 138 citations in OpenAlex.
- Time-Resolved Network Entropy Analysis Identifies a CTNND1-VAV3 Subnetwork in Gefitinib-Resistant NSCLC.International journal of molecular sciences · 2026Article
- Cancer signaling networks in tumor progression and drug resistance: Crosstalk, adaptive reprogramming and therapeutic targeting (Review).Oncology reports · 2026Review
- Cell Fate Dynamics Reconstruction Identifies TPT1 and PTPRZ1 Feedback Loops as Master Regulators of Differentiation in Pediatric Glioblastoma-Immune Cell Networks.Interdisciplinary sciences, computational life sciences · 2025Article
- Pharmacological approaches to understanding protein kinase signaling networks.Frontiers in pharmacology · 2023Review
- Article
- Perspectives on the landscape and flux theory for describing emergent behaviors of the biological systems.Journal of biological physics · 2022Review
- Tumor-specific activatable biopolymer nanoparticles stabilized by hydroxyethyl starch prodrug for self-amplified cooperative cancer therapy.Theranostics · 2022Article
- Neoantigen Controversies.Annual review of biomedical data science · 2021Review
- Identification of anticancer drug target genes using an outside competitive dynamics model on cancer signaling networks.Scientific reports · 2021Article
- Data-Driven Modeling of Breast Cancer Tumors Using Boolean Networks.Frontiers in big data · 2021Article
- Bayesian Structure Learning in Multi-layered Genomic Networks.Journal of the American Statistical Association · 2021Article
- Glioblastoma Stem Cells: Driving Resilience through Chaos.Trends in cancer · 2020Review
- Concepts in Boolean network modeling: What do they all mean?Computational and structural biotechnology journal · 2020Review
- Minimal intervening control of biomolecular networks leading to a desired cellular state.Scientific reports · 2019Article
- Systems biology: perspectives on multiscale modeling in research on endocrine-related cancers.Endocrine-related cancer · 2019Review
- Systems Pharmacogenomic Landscape of Drug Similarities from LINCS data: Drug Association Networks.Scientific reports · 2019Article
- A random walk-based method to identify driver genes by integrating the subcellular localization and variation frequency into bipartite graph.BMC bioinformatics · 2019Article
- WASABI: a dynamic iterative framework for gene regulatory network inference.BMC bioinformatics · 2019Article
- Dynamic Targeting in Cancer Treatment.Frontiers in physiology · 2019Article
- Typing tumors using pathways selected by somatic evolution.Nature communications · 2018Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cells employ highly dynamic signaling networks to drive biological decision processes. Perturbations to these signaling networks may attract cells to new malignant signaling and phenotypic states, termed cancer network attractors, that result in cancer development. As different cancer cells reach these malignant states by accumulating different molecular alterations, uncovering these mechanisms represents a grand challenge in cancer biology. Addressing this challenge will require new systems-based strategies that capture the intrinsic properties of cancer signaling networks and provide deeper understanding of the processes by which genetic lesions perturb these networks and lead to disease phenotypes. Network biology will help circumvent fundamental obstacles in cancer treatment, such as drug resistance and metastasis, empowering personalized and tumor-specific cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.